EDITORIAL article
Front. Genet.
Sec. Cancer Genetics and Oncogenomics
Volume 16 - 2025 | doi: 10.3389/fgene.2025.1679501
This article is part of the Research TopicEmerging Relevance of Molecular Profiling in Global Cancer Research and ManagementView all 6 articles
Editorial: Emerging Relevance of Molecular Profiling in Global Cancer Research and Management
Provisionally accepted
- 1University of Nebraska Medical Center, Omaha, United States
- 2Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
countries, these innovations have become integrated into standard clinical care, allowing for 30 treatments tailored to individual characteristics. However, these scientific have not translated into outcomes equally on a global scale. Significant disparities persist, 32 particularly in low-and middle-income countries, where access to molecular testing and targeted 33 therapies is limited. Bridging this gap requires sustained ongoing efforts to identify and validate 34 The Research Topic highlights the growing potential of biomarker discovery in advancing 92 personalized cancer care. By novel molecular insights and offering innovative 93 and prognostic this of research contributes to the evolution of precision oncology. 94 However, to realize the full potential of precision oncology on a global scale, continued research and 95 clinical validation must be paired with efforts to expand equitable access to molecular diagnostics 96 and targeted therapies globally, especially in under-resourced regions.
Keywords: Global cancer, tumor profiling, molecular mechanism, Biomarker Discovery, early diagnosis
Received: 04 Aug 2025; Accepted: 05 Aug 2025.
Copyright: © 2025 Leiphrakpam, Shukla and Are. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Premila Leiphrakpam, University of Nebraska Medical Center, Omaha, United States
Srijan Shukla, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India
Chandrakanth Are, University of Nebraska Medical Center, Omaha, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.